CWP291 / JW Pharma - LARVOL DELTA

The Small Molecule Inhibitor of the Wnt-β-Catenin Pathway, CWP232291, Inhibits Tumor Growth in Preclinical Models of Salivary Gland Adenoid Cystic Carcinoma. (PubMed, Head Neck) - "Abnormal Wnt-β-catenin signaling may play an active role in ACC pathogenesis, and its inhibition by CWP232291 may offer therapeutic potential, representing a promising avenue for further investigation."

Journal • Preclinical • Adenoid Cystic Carcinoma • Head and Neck Cancer • Oncology • Solid Tumor

Wnt/β-Catenin Inhibition by CWP232291 as a Novel Therapeutic Strategy in Ovarian Cancer. (PubMed, Front Oncol) - "Noticeably, CWP232291 could also s suppress the growth of cisplatin-resistant cell lines and ovarian cancer patient-derived organoids. Overall, this study has firstly demonstrated the anti-tumor effect of CWP232291 in ovarian cancer and proposed Wnt/β-catenin pathway inhibition as a novel therapeutic strategy against ovarian cancer."

Journal • Oncology • Ovarian Cancer • Solid Tumor • CTNNB1

Smad4 and p53 synergize in suppressing autochthonous intestinal cancer. (PubMed, Cancer Med) - "Smad4 loss and p53 loss are synergistic in autochthonous intestinal carcinogenesis, by downregulating p21 and activating Wnt/β-catenin pathway."

Journal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BCL2L1 • CD133 • SMAD4

Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients (clinicaltrials.gov) - P1b/2a; N=45; Active, not recruiting; Sponsor: JW Pharmaceutical; Trial completion date: Oct 2020 ➔ Oct 2022; Trial primary completion date: Oct 2020 ➔ Oct 2022

Clinical • Combination therapy • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Recent updates on Wnt signaling modulators: a patent review (2014-2020). (PubMed, Expert Opin Ther Pat) - "Lorecivivint, Wnt inhibitor, for the treatment of knee osteoarthritis and SM-04554, Wnt activator, for the treatment of androgenetic alopecia are currently under Phase III. Other molecules like LGK-974, RXC-004, ETC-159, CGX-1321, PRI-724, CWP-232291 and BC-2059 are also under different stages of clinical development for the treatment of cancer. Antibody based Wnt modulator, OTSA101-DTPA-90Y is currently under Phase I for the treatment of relapsed or refractory synovial sarcoma while OMP-18R5 is under Phase I for metastatic breast cancer. Ongoing preclinical and clinical trials will define the role of the Wnt pathway in different therapeutic areas and have opened new opportunities."

Journal • Review • Alopecia • Alzheimer's Disease • Breast Cancer • CNS Disorders • Hepatology • Immunology • Nephrology • Oncology • Osteoarthritis • Pain • Renal Disease • Rheumatology • Sarcoma • Solid Tumor • Synovial Sarcoma

[VIRTUAL] ANTI-TUMORIGENIC EFFECTS OF CWP232291, A FIRST-IN-CLASS INHIBITOR OF BETA-CATENIN/WNT PATHWAY IN ADENOID CYSTIC CARCINOMA. (AHNS 2021) - No abstract available

Adenoid Cystic Carcinoma • Oncology

CWP232291A suppresses the ovarian cancer growth via inhibition of Wnt/-catenin signaling pathway (AACR 2018) - "Taken together, CWP291 has more anticancer effect to ovarian cancer than standard chemo-agent, cisplatin. In conclusion, CWP291 provides a new therapeutic approach in ovarian cancer treatment."

Ovarian Cancer

CWP232291, a Wnt/β-catenin inhibitor, to suppress the growth and development of gastrointestinal cancers. (ASCO 2017) - "CWP232291 demonstrated synergistic activity with paclitaxel and irinotecan in the SNU-484 heterotopic xenograft. CWP232291 demonstrated significant preclinical efficacy in gastrointestinal tumors, especially in cancers with the β-catenin signaling activation."

Biosimilar • Gastric Cancer • Gastrointestinal Cancer • Gene Therapies • Leukemia • Oncology

Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients (clinicaltrials.gov) - P1; N=69; Completed; Sponsor: JW Pharmaceutical; Recruiting ➔ Completed

Trial completion • Acute Myelogenous Leukemia • Biosimilar • Fibrosis • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Oncology

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. (PubMed, Blood Adv) - P1 | "Future studies will explore CWP291, with a mechanism of action aimed at eradication of earlier progenitors via Wnt pathway blockade, as combination therapy. This trial was registered at www.clinicaltrials.gov as #NCT01398462."

Clinical • Journal • P1 data • Acute Myelogenous Leukemia • CNS Disorders • Dermatology • Dermatopathology • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Oncology • Pain • Pneumonia • Pulmonary Disease • Renal Disease • Respiratory Diseases • Septic Shock • CTNNB1

The small molecule WNT/β-catenin inhibitor CWP232291 blocks the growth of castration-resistant prostate cancer by activating the endoplasmic reticulum stress pathway. (PubMed, J Exp Clin Cancer Res) - "Beyond providing preclinical evidence of therapeutic efficacy for the novel small molecule β-catenin inhibitor CWP232291 in CRPC, our results show that inducing ER stress and targeting WNT/β-catenin signaling may be a novel strategy against CRPC."

Journal

JW completes P1 trials for target anticancer treatment (Korea Biomedical Review) - P1a/1b, N=25; NCT02426723; Sponsor: JW Pharmaceutical; "The company launched phase 1a clinical trials for CWP291 on 11 patients with relapsed or refractory multiple myeloma in the U.S. and Korea in 2015 while starting phase 1b clinical trials that use CWP291 in combination with lenalidomide and dexamethasone on eight patients last year....According to the results report, in the CWP291 monotherapy study, about 46 percent of the clinical patients showed a stable disease best overall response, while 42 percent showed stable disease best overall response in a combination regimen."

P1 data

Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients (clinicaltrials.gov) - P1a/1b; N=25; Completed; Sponsor: JW Pharmaceutical; Recruiting ➔ Completed; N=60 ➔ 25; Trial completion date: Sep 2019 ➔ Oct 2018; Trial primary completion date: Sep 2019 ➔ Oct 2018

Clinical • Combination therapy • Enrollment change • Trial completion • Trial completion date • Trial primary completion date

Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients (clinicaltrials.gov) - P1b/2a; N=45; Active, not recruiting; Sponsor: JW Pharmaceutical; Recruiting ➔ Active, not recruiting

Clinical • Combination therapy • Enrollment closed